Research and development expenditure accounts for 45%, core technology leads the industry continuously, and Xinghuo Medical's large model tops the Medbench ranking.

According to the Wise Finance App, as disclosed by the Hong Kong Stock Exchange, Xunfei Medical (02506) released its mid-term performance for 2025 on August 20. In the first half of the year, the company achieved a revenue of 2.986 billion yuan, a year-on-year increase of 30%, and a gross profit of 1.539 billion yuan, a year-on-year increase of 27%. The gross profit margin remained at a high level of 51.5%, with profitability and growth continuing to lead the industry.